HeartBeat.bio AG logo

HeartBeat.bio AG

REINVENTING CARDIAC DRUG DISCOVERY

22 employees · est. 2021 · Vienna, Austria

VS
Nuevocor logo

Nuevocor

Pioneering novel therapies for untreatable cardiac diseases

29 employees · est. 2021 · Singapore, Singapore

Side-by-Side Comparison

HeartBeat.bio AG Nuevocor
Founded
2021 2021
Headquarters
Vienna, Austria Singapore, Singapore
Employees
22 29
Industry
Biotechnology Biopharma, Biotechnology, Pharmaceutical
Funding Stage
Seed Series B
Total Funding
$6.00M $80.60M
Funding Rounds
2 3
Services
Not tracked yet Development of novel therapies for cardiomyopathies, Genetic medicine research and development, Mechanobiology-centered treatment approaches
Target Customers
Not tracked yet Patients with untreatable cardiomyopathies, Healthcare providers specializing in cardiology, Research institutions focusing on cardiovascular diseases
Taxonomy
Cardiac Organoids, Drug Discovery, Heart Failure, Cardiomyopathy, Myocardial Infarction, 3D Disease Modelling, High-Throughput Screening, Cardiovascular Regeneration, Cardiotoxicity, Cardio-Oncology, IPS Cells, AI-supported Analysis, Genetic Cardiomyopathies, Vienna BioCenter Genetic Medicines, Cardiomyopathies, Gene Therapy, Cardiac Function Restoration, PrOSIA Mechanobiology Platform, Preclinical-stage, Biopharmaceutical Company, Genetic Cardiomyopathies, Novel Therapies, Cardiac Diseases, Disease Treatment
Website
heartbeat.bio nuevocor.com
HeartBeat.bio AG logo

About HeartBeat.bio AG

HeartBeat.bio AG is a biotechnology startup that aims to reinvent cardiac drug discovery through its innovative approach. The company, founded in 2021 and headquartered in Austria, is focusing on the development of a high-throughput human organoid cultivation, screening, and AI-supported data analys...

Nuevocor logo

About Nuevocor

Nuevocor, founded in 2021, is a pioneering company in the Biopharma, Biotechnology, and Pharmaceutical industries. With its headquarters nestled in Singapore and operational reach extending to the USA, Nuevocor is at the forefront of developing genetic medicines targeted at previously untreatable ge...

We will tell you when either one moves

BounceWatch watches HeartBeat.bio AG and Nuevocor for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at HeartBeat.bio AG and Nuevocor — by email.

Frequently Asked Questions

HeartBeat.bio AG — REINVENTING CARDIAC DRUG DISCOVERY. Nuevocor — Pioneering novel therapies for untreatable cardiac diseases. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
HeartBeat.bio AG has raised $6.00M while Nuevocor has raised $80.60M.
HeartBeat.bio AG and Nuevocor operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare HeartBeat.bio AG with someone else

Start typing a company name or domain.

Related Comparisons

Compiled from the BounceWatch company index. We last looked at HeartBeat.bio AG on 11 Sep 2024, and Nuevocor on 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes